Diagnostic tools: Various tests to diagnose and manage hepatitis C including various biochemical marker, imaging, liver biopsy for grading/staging liver disease and HCV RNA (viral load) tests.

 

        Biochemical/Imaging

o       212. Independent evaluation of 4 blood scores of liver fibrosis in chronic hepatitis C: FibroMeter, Fibrotest, Hepascore and APRI

o       219. A simple and economical score can often displace other invasive or costly methods to evaluate liver fibrosis in chronic hepatitis C virus infection

o       221. A Single Tube Multiplex Research Assay to Assess the Risk of Cirrhosis in Subjects with Chronic Hepatitis C

o       223. Direct serological markers of liver fibrogenesis improve the diagnostic accuracy of indirect markers for liver fibrosis in chronic hepatitis C patients

o       224. Reproducibility of blood scores of liver fibrosis

o       226. The AST to Platelet Ratio Index Does Not Accurately Predict Significant Fibrosis in HCV/HIV Coinfected Patients with Low CD4 T Cell Counts

o       231. Optimization of the diagnosis of cirrhosis comparing clinical, biochemical and radiological features with liver stiffness by FibroScan

o       232. Transient elastography in chronic hepatitis C - comparison between different noninvasive methods for liver fibrosis assessment

o       234. A screening test for thrombosis risk factors as a new biological marker of liver fibrosis in patients with chronic hepatitis C virus (HCV) infection

o       235. Accurate Identification of Liver Fibrosis by a Continuous 13C Methacetin Breath Test in Patients with Chronic HCV Infection and Normal or Near-Normal Liver Enzymes

o       237. Increased Anti-ARFP Antibody Positivity is Associated with End-Stage Liver Disease

o       238. Diagnostic accuracy of blood tests of liver fibrosis for severe fibrosis and cirrhosis in patients with chronic viral hepatitis

o       239. Meta-analysis of blood scores for liver fibrosis in chronic hepatitis C

o       243. Diffusion-weighted MR imaging for the diagnosis of liver fibrosis in patients with chronic hepatitis C (updated October 28, 2006)

o       249. European liver fibrosis (ELF) markers accurately distinguish fibrosis severity in Chronic Hepatitis C (CHC); an external validation study in a population-based cohort

o       250. FIBROSpect II and Image Analysis in the Evaluation of Chronic Hepatitis C

o       341. Evaluation of fibrosis regression using non-invasive methods in very long-term follow-up of HCV responder patients

o       354. Transient elastography (fibroscan) in chronic hepatitis C. Will it modify the assessment and the follow-up of treated patients?

o       373. The international autoimmune hepatitis group scoring system in patients with Chronic Hepatitis C and serum autoantibodies undergoing interferon/ribavirin therapy: a prospective validation study

o       391. Evaluation of fibrosis evolution using non-invasive methods according to sustained virological response in HCV patients. A pilot prospective controlled study

o       702. Assessment of the severity of cirrhosis according to different values of FibroScan : a prospective study (updated October 29, 2006)

o       705. A preliminary evaluation of a novel biomarker of renal function, Neutrophil Gelatinase-Associated Lipocalin (NGAL), in patients with liver disease

o       707. Noninvasive diagnosis of the degree of hepatic fibrosis using serum markers and ultrasonography in patients with chronic hepatitis B

o       709. Liver stiffness measurement by transient elastography: predictive factors of accuracy, success and reproducibility (updated October 29, 2006)

o       710. Combination of blood scores, Doppler ultrasonography, and transient elastography for the diagnosis of liver fibrosis (updated October 29, 2006)

o       720. Enhanced Quantitative Liver Spleen Scan (QLSS) Prediction of Liver Disease Severity in Baseline HALT-C Patients with Moderate Fibrosis or Cirrhosis

o       743. Liver stiffness measurement by transient elastrography (Fibroscan): is training necessary?

o       749. Prospective assessment of liver stiffness for the non-invasive diagnosis of portal hypertension (updated October 30, 2006)

o       1148. Prospective Comparison of Two Commercial Non-invasive Fibrosis Serum Marker Panels (FibroSure and FibroSpect II) Before and During Therapy with albumin interferon alfa-2b in A Chronic HCV Genotype 1 Population (updated October 31, 2006)

 

        Biopsy

o       165. Longitudinal analysis of fibrosis progression in chronic hepatitis C using analysis of multiple biopsies and Generalized Estimating Equations (GEE)

o       506. Prospective Audit of Liver Biopsy Practice: Is Bigger Better? (updated October 31, 2006)

o       507. Patient Experience of Day Case Liver Biopsy: Prospective Audit (updated October 29, 2006)

        General

o       689. Validation of the Short Form of Liver Disease Quality of Life (LDQOL) Instrument

o       692. A simple scoring system accurately predicts outcome in patients with chronic liver disease admitted to a Liver Intensive Care Unit

o       700. Hand grip test is a valuable tool for screening of malnutrition in patients with liver cirrhosis: prospective analysis in 138 patients (updated October 29, 2006)

 

        Viral load

o       213. Hepatitis virus C RNA quantification by automated Cobas AmpliPrep-Cobas TaqMan 48 (CAP-CTM) real-time PCR assay: an evaluation of performance

o       225. Evaluation of an automated, highly sensitive, real time PCR based assay (COBAS ampliprep / COBAS taqman) for quantification of HCV RNA

o       233. Ultracentrifugation of serum samples allows detection of HCV-RNA in patients with occult HCV infection

o       236. Accurate quantification and sensitive detection of hepatitis C virus RNA using a single automated assay in the clinical setting.